Cagrilintide complete guide

Cagrilintide is a synthetic long-acting amylin analog developed in the Novo Nordisk research program and engineered for once-weekly administration in research-design protocols. Native human amylin — also called Islet Amyloid Polypeptide (IAPP) — is a 37-amino-acid peptide co-secreted with insulin from pancreatic beta cells in response to nutrient intake. Its physiological roles, documented across decades of published amylin literature, include slowing gastric emptying, suppressing post-prandial glucagon secretion, and promoting meal-related satiety via central appetite-regulatory circuits. Native amylin is short-acting (plasma half-life ~13 minutes) and highly aggregation-prone, forming the amyloid fibrils characteristic of type-2 diabetes islet deposits. Pramlintide (Symlin), the first stabilized amylin analog approved in 2005, established that amylin agonism could be made therapeutically tractable; Cagrilintide is the next-generation long-acting analog built to inherit that mechanism on a once-weekly research-design timescale.

Cagrilintide’s prominence in current published literature comes from its role as the partner peptide to Semaglutide in the Cagrisema combination-research program. Cagrisema (Cagrilintide + Semaglutide) is in Novo Nordisk phase 3 REDEFINE research-clinical trials (2024–2025), with published phase 1 and phase 2 outcomes documenting body-weight reductions in research populations exceeding monotherapy with either compound. This positions Cagrilintide as one of the most actively cited “second-class” partner peptides in modern fat-loss research literature, and the canonical example of cross-class agonist combination — pairing GLP-1 receptor agonism (Semaglutide) with amylin/calcitonin receptor agonism (Cagrilintide) on non-overlapping satiety pathways.

Quick reference — Cagrilintide identifiers

Property	Cagrilintide
Class	Long-acting amylin analog · dual AMY/CT receptor agonist
CAS number	1415456-99-3
Synonyms / development codes	NN9838, AM833
Receptor targets	AMY1, AMY2, AMY3 (amylin receptors) · CTR (calcitonin receptor)
Sequence length	37 amino acids (modified human amylin backbone)
Backbone modification	Multiple aa substitutions for aggregation resistance + C-terminal C20 fatty-acid (icosanedioic acid) for albumin binding
Molecular formula (approx.)	~C198H316N56O59S
Molecular weight (approx.)	~4416 g/mol
Half-life (research models)	~7–9 days (once-weekly)
Origin	Rationally designed long-acting analog of native human amylin (Novo Nordisk research program)
Vial strengths (TogoPeptide)	5 mg lyophilized

Origin and structure — long-acting amylin engineering

Native human amylin is a 37-amino-acid peptide co-released with insulin from pancreatic beta cells in response to nutrient intake. It signals through the amylin receptor family — heterodimeric complexes of the calcitonin receptor (CTR) with the receptor-activity-modifying proteins RAMP1, RAMP2, and RAMP3, producing the AMY₁, AMY₂, and AMY₃ receptor subtypes. Despite its physiological importance, native amylin has two structural problems that made it intractable as a research-protocol peptide: a very short plasma half-life (~13 minutes), and a strong tendency to form amyloid fibrils, the islet-amyloid deposits historically associated with beta-cell dysfunction in T2D [6].

Pramlintide, approved in 2005, was the proof-of-concept that amylin signaling could be stabilized: three amino-acid substitutions (positions 25, 28, 29) replacing aggregation-prone residues with proline, yielding a soluble peptide with a plasma half-life of approximately 48 minutes and clinical use in the diabetes research literature. Cagrilintide builds on that proof-of-concept with a more substantial structural overhaul: multiple substitutions throughout the amylin sequence to disrupt aggregation pathways, plus the addition of a C-terminal C20 fatty-acid moiety (icosanedioic acid) for reversible serum-albumin binding. This albumin-binding strategy is conceptually parallel to Semaglutide’s C18 fatty-acid + γ-Glu spacer modification — once Cagrilintide reversibly binds albumin in plasma, it is shielded from glomerular filtration and circulates as a slow-release depot, extending half-life from native amylin’s ~13 minutes to Cagrilintide’s ~7–9 days [1].

Mechanism — AMY and CT receptor agonism

AMY receptor activation

Cagrilintide binds and activates the amylin receptor family — AMY₁, AMY₂, and AMY₃ heterodimers formed by the calcitonin receptor pairing with RAMP1, RAMP2, and RAMP3 respectively. Activation drives the canonical amylin physiological program documented across published literature: slowed gastric emptying, suppression of post-prandial glucagon release from pancreatic alpha cells, and promotion of meal-related satiety through central nervous system effects on appetite-regulatory regions including the area postrema (AP), the nucleus tractus solitarius (NTS), and downstream hypothalamic circuits.

CT (calcitonin) receptor activation

Cagrilintide also binds the calcitonin receptor itself in addition to the AMY heterodimers. Calcitonin-receptor signaling contributes additional inputs into bone-metabolism research pathways and adds further appetite-regulatory tone, broadening the receptor-coverage profile beyond pure amylin signaling and distinguishing Cagrilintide from a strictly AMY-selective ligand.

Satiety and food-intake research

Published research consistently documents Cagrilintide effects on food intake across research-animal models and human research-clinical investigations: reduced caloric intake, reduced ad-libitum food consumption, increased per-meal satiation, and reduced hunger ratings on standardized research scales. The food-intake-suppression mechanism is canonically attributed to central amylin-receptor activation in hindbrain and hypothalamic appetite-regulatory circuits [5].

Synergy with GLP-1 agonism — the Cagrisema rationale

The mechanistic rationale for Cagrisema combination research is that GLP-1 receptor agonism (Semaglutide) and amylin/CT receptor agonism (Cagrilintide) act through non-overlapping satiety pathways. GLP-1 receptor activation drives satiety primarily via hindbrain GLP-1R-expressing neurons in the NTS and projections to the central amygdala and hypothalamic feeding circuits. Amylin receptor activation drives satiety via the area postrema (an adjacent but distinct hindbrain nucleus) and via separate hypothalamic projections. Combined activation produces super-additive food-intake reduction in research models — providing the mechanistic basis for why combination Cagrisema research outcomes consistently exceed monotherapy with either compound alone.

Cagrisema combination research literature

The Cagrisema research program documents Cagrilintide co-administered with Semaglutide 2.4 mg in research-clinical settings. Phase 1 research (Enebo et al., 2021) established the pharmacokinetic and tolerability profile of concomitant administration and demonstrated proof-of-concept body-weight effects [3]. Phase 2 dose-finding research extended these findings with longer treatment durations, reporting body-weight reductions in research populations on the order of ~15–17% at trial endpoint, compared with approximately ~10–12% for Semaglutide monotherapy in matched research-trial settings [4].

Phase 3 REDEFINE-1 (general obesity research populations) and REDEFINE-2 (T2D research populations) are the ongoing 2024–2025 large-scale trials for Cagrisema. These are research-clinical-translational studies — not licensed therapy — and their published outcomes form the largest body-weight signal in modern obesity research literature. The Cagrisema corpus is the canonical present-day reference point for cross-class combination research designs.

Cagrilintide monotherapy research

Foundational Cagrilintide monotherapy research was published as a multicentre, randomised, double-blind, placebo-controlled and active-controlled (vs liraglutide) dose-finding phase 2 trial (Lau et al., 2021). In research populations with overweight or obesity, once-weekly Cagrilintide produced body-weight reductions of approximately ~10–11% at the highest tested dose at 26 weeks, with a tolerability profile dominated by gastrointestinal effects consistent with the amylin-class mechanism [1]. The magnitude is smaller than Cagrisema combination outcomes, but the monotherapy signal is mechanistically clean — it isolates the pure amylin/CT pathway contribution from the GLP-1 contribution in the combined regimen.

Glucose-metabolism and gastric-emptying research

Beyond body-weight endpoints, the published Cagrilintide research literature documents the canonical amylin physiological effects in long-acting form: reductions in post-prandial glucose excursions attributable to slowed gastric emptying, suppression of post-prandial glucagon secretion from pancreatic alpha cells, and reductions in HbA1c in T2D research populations. These effects replicate native amylin’s documented physiology at a once-weekly research-design timescale, providing the metabolic-research basis for Cagrilintide’s use in T2D combination research arms.

Cagrilintide vs Pramlintide vs native amylin

Compound	Modification	Half-life	Research framing
Native amylin (IAPP)	None	~13 min	Physiology-research only — aggregation issues prevent direct protocol use
Pramlintide	3 aa substitutions (Pro at 25, 28, 29) for solubility	~48 min	FDA-approved (Symlin) for T1D / T2D — short-acting reference analog
Cagrilintide	Multiple aa substitutions + C20 fatty-acid for albumin binding	~7–9 days	Once-weekly long-acting research analog · Cagrisema partner peptide

Storage and handling

Cagrilintide ships as lyophilized powder. Research-handling literature for long-acting amylin analogues documents:

• Lyophilized state: sealed at −20°C, protected from light. Stable for the manufacturer-stated window — typically 24+ months under proper storage.
• Diluent: bacteriostatic water (0.9% benzyl alcohol) is the standard reconstitution diluent. The benzyl alcohol enables multi-puncture access across approximately 28 days under refrigeration.
• Reconstituted state: refrigerate at 2–8°C immediately after reconstitution; documented research-handling window is approximately 28 days under refrigerated conditions.
• Avoid freeze-thaw cycles after reconstitution — albumin-binding peptide-fatty-acid conjugates are sensitive to repeated phase changes. Single freeze with refrigerated storage thereafter is the documented approach for this class.
• Aggregation sensitivity: the amylin backbone, even after aggregation-resistance substitutions, retains some surface-adsorption sensitivity. For research designs requiring extended in-vitro storage, low-protein-binding tubes are documented in the handling literature.
• Vial inspection: clear solution after reconstitution. Cloudiness, particulates, or visible aggregation indicate compound or microbial compromise; discard and re-reconstitute fresh.

Each TogoPeptide Cagrilintide shipment includes a per-batch Certificate of Analysis with HPLC purity (target ≥98%), mass-spectrometry identity confirmation, lot number, manufacture date, analysis date. See how to read a COA for line-by-line documentation, or reconstitution methodology for the diluent volume math.

Cross-research lines and pairings

• Cagrisema research design: Cagrilintide co-administered with Semaglutide is the canonical present-day combination-research configuration, with the largest body-weight signal in published modern obesity-research literature. Pairing the Cagrilintide product page with the Semaglutide product page provides matched lots for cross-class combination research.
• Cross-class comparison designs: research designs pairing Cagrilintide with Tirzepatide (GIP/GLP-1 dual agonist) or Retatrutide (GIP/GLP-1/glucagon triple agonist) extend the cross-class strategy beyond Semaglutide. See the GLP-1 agonists compared article for matched identifiers across the incretin-class compounds.
• Curated stack option: the Fat-Loss Stack bundles canonical fat-loss research compounds with included bacteriostatic water and syringes for cross-generation comparison research designs.
• Reconstitution methodology: the reconstitution calculator computes diluent volume for any vial mass × target concentration combination — including the 5 mg Cagrilintide vial.

Closing

Cagrilintide is the canonical long-acting amylin analog in current research literature — a 37-amino-acid amylin backbone re-engineered with multiple aggregation-resistance substitutions and a C20 fatty-acid albumin-binding moiety to support once-weekly research-design protocols. Its mechanism (AMY + CT receptor agonism) acts on satiety pathways non-overlapping with GLP-1 signaling, providing the mechanistic rationale for the Cagrisema combination program — currently the largest published cross-class body-weight signal in modern obesity research.

This guide documents what published peer-reviewed research has investigated. It is structural and mechanism context for laboratory researchers, not therapeutic recommendation, not protocol guidance, not a basis for self-administration of any kind.

Source Cagrilintide for laboratory research:

• Cagrilintide product page — full identifiers, 5 mg vial, per-batch COA
• Fat-Loss Stack — curated cross-class fat-loss research bundle
• Fat-loss research compounds — full category listing

For methodology and laboratory-handling questions, contact our research-supply team at info@togopeptide.com.